These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34093711)

  • 1. HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells.
    Kwon YW; Ahn HS; Lee JW; Yang HM; Cho HJ; Kim SJ; Lee SH; Yang HM; Jang HD; Kim SJ; Kim HS
    Stem Cells Int; 2021; 2021():8873383. PubMed ID: 34093711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.
    Kitano Y; Nishimura S; Kato TM; Ueda A; Takigawa K; Umekage M; Nomura M; Kawakami A; Ogawa H; Xu H; Hotta A; Takasu N; Tsukahara M
    Mol Ther Methods Clin Dev; 2022 Sep; 26():15-25. PubMed ID: 35755947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
    Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β2 Microglobulin Knockout Induced Pluripotent Stem Cells.
    Zha S; Tay JC; Zhu S; Li Z; Du Z; Wang S
    Cell Transplant; 2020; 29():963689720965529. PubMed ID: 33172291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic correction of induced pluripotent stem cells mediated by transcription activator-like effector nucleases targeting ALPL recovers enzyme activity and calcification in vitro.
    Nakano C; Kitabatake Y; Takeyari S; Ohata Y; Kubota T; Taketani K; Kogo M; Ozono K
    Mol Genet Metab; 2019 Jun; 127(2):158-165. PubMed ID: 31178256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice.
    Sun YQ; Zhang Y; Li X; Deng MX; Gao WX; Yao Y; Chiu SM; Liang X; Gao F; Chan CW; Tse HF; Shi J; Fu QL; Lian Q
    Stem Cells; 2015 Dec; 33(12):3452-67. PubMed ID: 26175298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts.
    Sasaki H; Wada H; Baghdadi M; Tsuji H; Otsuka R; Morita K; Shinohara N; Seino K
    Transplantation; 2015 Nov; 99(11):2301-10. PubMed ID: 26360665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future perspectives of HLA-edited induced pluripotent stem cells.
    Koga K; Wang B; Kaneko S
    Inflamm Regen; 2020; 40():23. PubMed ID: 33014207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.
    Torikai H; Reik A; Soldner F; Warren EH; Yuen C; Zhou Y; Crossland DL; Huls H; Littman N; Zhang Z; Tykodi SS; Kebriaei P; Lee DA; Miller JC; Rebar EJ; Holmes MC; Jaenisch R; Champlin RE; Gregory PD; Cooper LJ
    Blood; 2013 Aug; 122(8):1341-9. PubMed ID: 23741009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for immune regulation in iPS cell-based cardiac regenerative medicine.
    Murata K; Ikegawa M; Minatoya K; Masumoto H
    Inflamm Regen; 2020; 40():36. PubMed ID: 33005258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro induction of endothelial HLA class II antigen expression by cytomegalovirus-activated CD4+ T cells.
    Waldman WJ; Knight DA; Adams PW; Orosz CG; Sedmak DD
    Transplantation; 1993 Dec; 56(6):1504-12. PubMed ID: 7904091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications.
    Chang CY; Ting HC; Su HL; Jeng JR
    Cell Transplant; 2018 Mar; 27(3):379-392. PubMed ID: 29806481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple Populations.
    Lee S; Huh JY; Turner DM; Lee S; Robinson J; Stein JE; Shim SH; Hong CP; Kang MS; Nakagawa M; Kaneko S; Nakanishi M; Rao MS; Kurtz A; Stacey GN; Marsh SGE; Turner ML; Song J
    Stem Cells; 2018 Oct; 36(10):1552-1566. PubMed ID: 30004605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-the-Shelf, Immune-Compatible Human Embryonic Stem Cells Generated Via CRISPR-Mediated Genome Editing.
    Kim A; Lee KG; Kwon Y; Lee KI; Yang HM; Habib O; Kim J; Kim ST; Kim SJ; Kim JS; Hwang DY
    Stem Cell Rev Rep; 2021 Jun; 17(3):1053-1067. PubMed ID: 33423156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.
    Sackett SD; Brown ME; Tremmel DM; Ellis T; Burlingham WJ; Odorico JS
    Transplant Rev (Orlando); 2016 Apr; 30(2):61-70. PubMed ID: 26970668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene correction in patient-specific iPSCs for therapy development and disease modeling.
    Jang YY; Ye Z
    Hum Genet; 2016 Sep; 135(9):1041-58. PubMed ID: 27256364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines.
    Cerbini T; Funahashi R; Luo Y; Liu C; Park K; Rao M; Malik N; Zou J
    PLoS One; 2015; 10(1):e0116032. PubMed ID: 25587899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
    Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
    J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.